APRINOIA Therapeutics
We are a Phase 3 clinical biotech developing drug candidates to treat neurodegenerative diseases. (Incorporated in the Cayman Islands) We are a clinical-stage biotechnology company committed to protecting patients’ brain health and changing clinical outcomes for a broad range of neurodegenerative diseases by developing novel, highly sensitive and selective diagnostic tools and novel therapeutics. Our […]
February 26, 2024 Read More